BioXcel Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BTAI and other ETFs, options, and stocks.

About BTAI

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. 

CEO
Vimal D. Mehta
CEOVimal D. Mehta
Employees
29
Employees29
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2017
Founded2017
Employees
29
Employees29

BTAI Key Statistics

Market cap
31.00M
Market cap31.00M
Price-Earnings ratio
-0.16
Price-Earnings ratio-0.16
Dividend yield
Dividend yield
Average volume
575.72K
Average volume575.72K
High today
High today
Low today
Low today
Open price
$1.17
Open price$1.17
Volume
2.37K
Volume2.37K
52 Week high
$8.08
52 Week high$8.08
52 Week low
$1.01
52 Week low$1.01

Stock Snapshot

As of today, BioXcel Therapeutics(BTAI) shares are valued at $1.14. The company's market cap stands at 31M, with a P/E ratio of -0.16.

On 2026-05-18, BioXcel Therapeutics(BTAI) stock opened at $1.17, reached a high of —, and a low of —.

The BioXcel Therapeutics(BTAI)'s current trading volume is 2.37K, compared to an average daily volume of 575.72K.

During the past year, BioXcel Therapeutics(BTAI) stock moved between $1.01 at its lowest and $8.08 at its peak.

During the past year, BioXcel Therapeutics(BTAI) stock moved between $1.01 at its lowest and $8.08 at its peak.

BTAI News

Nasdaq 3d
BioXcel Therapeutics, Inc. Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to los...

BioXcel Therapeutics, Inc. Reports Q1 Loss, Lags Revenue Estimates
TipRanks 3d
BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

Reports Q1 revenue $206,000, consensus $381,490. “The first quarter was marked by tremendous progress, achieving a major regulatory milestone and developing the...

People also own

Based on the portfolios of people who own BTAI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.